ArticlePloS one2026

Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma.

Kyowon Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.